Correspondence to Editorial 2 on "Genomic Biomarkers to Predict Response to Atezolizumab Plus Bevacizumab Immunotherapy in Hepatocellular Carcinoma: Insights From the IMbrave150 Trial"

Authors

Sun Young Yim
Sung Hwan Lee
Ji Hoon Kim
Sunyoung S Lee
Ahmed O Kaseb
Ju-Seog Lee

Language

English

Publication Date

1-1-2025

Journal

Clinical and Molecular Hepatology

DOI

10.3350/cmh.2024.0830

PMID

39370715

PMCID

PMC11791551

PubMedCentral® Posted Date

10-7-2024

PubMedCentral® Full Text Version

Post-print

Published Open-Access

yes

Recommended Citation

Yim, Sun Young; Lee, Sung Hwan; Kim, Ji Hoon; et al., "Correspondence to Editorial 2 on "Genomic Biomarkers to Predict Response to Atezolizumab Plus Bevacizumab Immunotherapy in Hepatocellular Carcinoma: Insights From the IMbrave150 Trial"" (2025). Faculty, Staff and Student Publications. 6061.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/6061